⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLKW News
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
globenewswire.com
OTLK
OTLKW